Introduction {#sec1}
============

Rotator cuff tear (RCT) is a common injury among the elderly and it is characterized by pain, activity limitation and sleep disturbance \[[@B1]\]. These patients require consultations, physiotherapy, radiological examinations and surgery, leading to a considerable economic burden \[[@B2]\]. However, the etiology of RCT is poorly understood. There is evidence that patient's age, tear size and tendon conformation are associated with the development of RCT \[[@B3],[@B4]\]. Additionally, genetic factors play an important role in modifying an individual's risk of RCT.

A normal tendon consists mainly of collagen fibrils \[[@B5]\]. Increased expression of type I and type III collagens in the ruptured tendon of a rotator cuff has been previously reported \[[@B6]\]. Increased expression of some extracellular matrix (ECM) proteins was observed in injured tendons \[[@B7]\]. Matrix metalloproteinases (MMPs) are a large group of proteolytic enzymes responsible for tissue remodeling and ECM degradation \[[@B8]\]. Increased expression of MMPs 1 and 9 as well as decreased MMP-3 expression is detected in torn RCT tissue \[[@B9]\]. MMP-1 is a protease that breaks down type I collagen fibers \[[@B10]\]. MMP-3 is involved in the degradation of various collagens and regulation and activation of MMPs \[[@B11]\].

The MMP-1 rs1799750 (1G\>2G) and MMP-3 rs3025058 (6A\>5A) polymorphisms, which are located in the promoter region of the MMP gene, are related to the expression and activity of these enzymes \[[@B12]\]. An association of rs1799750/rs3025058 polymorphism with increased risk of RCT has been reported in a Brazilian population \[[@B13]\]. However, this significant association has not been confirmed in the Chinese population. Therefore, this hospital-based case--control study was performed to investigate the role of rs1799750/rs3025058 polymorphisms in the risk of RCT.

Materials and methods {#sec2}
=====================

Study subjects {#sec2-1}
--------------

In the present study, 150 patients with RCT and 150 healthy controls were recruited from the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, the Second Affiliated Hospital of Jiaxing University and the Second Affiliated Hospital of Zhejiang University School of Medicine in China between September 2014 and July 2018. Patients with large to massive RCT in one or both shoulders documented by magnetic resonance imaging were included in the study, while patients with tendinopathy, calcifying tendinitis or inflammatory disease were excluded. All control individuals had intact supraspinatus, infraspinatus and subscapularis tendons in both shoulders. Individuals of the control group were selected among the ones receiving a routine health examination and without family history of RCT. Exclusion criteria for controls were a history of humeral fracture and shoulder treatment in the past 2 years. A self-designed questionnaire was used to collect demographic and clinical characteristics (age, gender, smoking habits, hypertension, tendinopathies in other joints and existence of relatives who previously had treatment for RCT) of RCT cases and control subjects.

The present study was approved by the Ethics Committees of the three hospitals from which participants were recruited. All subjects provided written informed consent prior to participation in the study.

Isolation of DNA and genotyping {#sec2-2}
-------------------------------

Genomic DNA was isolated from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. The concentration and purity of the extracted DNA were estimated by the measurement of the optical density at 260/280 nm. Genotyping was performed by polymerase chain reaction (PCR) and direct sequencing. The primers were designed using Primer-BLAST and were synthesized commercially by GenScript Inc. (Nanjing, China). The primers used for the present study were as follows: Forward: 5′-TCGTGAGAATGTCTTCCCATT-3′, Reverse: 5′-TCTTGGATTGATTTGAGATAAGTGAAATC-3′ for MMP-1 rs1799750 polymorphism; Forward: 5′-GGTTCTCCATTCCTTTGATGGGGGGAAAGA-3′, Reverse: 5′-CTTCCTGGAATTCACATCACTGCCACCACT-3′ for MMP-3 rs3025058 polymorphism. PCR amplification was performed in a 25-μl reaction volume containing 1 μl genomic DNA, 2 μl of 2.5 mM dNTPs, 2.5 μl of 10× Taq buffer, 1 μl each primer (10 mM), 0.125 μl Taq and ddH~2~O. The PCR amplification involved preliminary denaturation at 95°C for 5 min, followed by 33 cycles of 30 s at 94°C, 30 s at 55°C, 45 s at 72°C and one final cycle of 10 min at 72°C. The PCR products were separated by 2% agarose gel electrophoresis and visualized by Ethidium Bromide staining (Invitrogen, Grand Island, U.S.A.). The amplified DNA was sequenced by GenScript Inc. (Nanjing, China). A random selection of (3%) was used to validate the genotyping results in a blinded manner; the results were 100% concordant.

Statistical analyses {#sec2-3}
--------------------

Statistical analysis was performed using the SAS software package (var. 9.1.3; SAS Institute, Cary, NC, U.S.A.). The demographic and clinical characteristics of study participants were evaluated using Student's *t* test (for continuous variables) or a chi-squared test (for categorical variables). Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the association between MMP1/3 gene polymorphisms and risk of RCT by logistic regression analyses with adjustment for relevant significant variables under the allelic, recessive, dominant, homozygous and heterozygous models. Subgroup analyses were performed according to gender, smoking and drinking habits, age, individuals with/without hypertension, diabetes and thyroid disease. Departure from Hardy--Weinberg equilibrium (HWE) for MMP1/3 genotype distributions in controls was evaluated using a goodness-of-fit chi-squared test. *P*\<0.05 was considered statistically significant.

Results {#sec3}
=======

Characteristics of the study population {#sec3-1}
---------------------------------------

The baseline characteristics of the study population are listed in [Table 1](#T1){ref-type="table"}. The average age of the patients was 52.25 years compared with 54.17 years of the controls, with no statistically significant difference between the two groups. No significant difference was found between the two groups with regard to gender, hypertension and thyroid disease, whereas a significant difference was observed in the distribution of smokers (*P*=0.005), drinkers (*P*=0.001) and individuals with diabetes (*P*=0.023). Details of the family history, tear size and pre-operative stiffness in RCT patients are also shown in [Table 1](#T1){ref-type="table"}.

###### Patient demographics and risk factors in RCT

  Characteristics           Case (*n*=150)   Control (*n*=150)   *P*
  ------------------------- ---------------- ------------------- -------
  Age                       52.25 ± 10.67    54.17 ± 11.10       0.128
  Sex                                                            0.166
    Male                    82 (54.7%)       70 (46.7%)          
    Female                  68 (45.3%)       80 (53.3%)          
  Smoking                                                        0.005
    Yes                     71 (47.3%)       47 (31.3%)          
    No                      79 (52.7%)       103 (68.7%)         
  Alcohol                                                        0.001
    Yes                     83 (55.3%)       53 (35.3%)          
    No                      67 (44.7%)       97 (64.7%)          
  Hypertension                                                   0.699
    Yes                     43 (28.7%)       40 (26.7%)          
    No                      107 (71.3%)      110 (73.3%)         
  Diabetes                                                       0.023
    Yes                     39 (26.0%)       23 (15.3%)          
    No                      111 (74.0%)      127 (84.7%)         
  Thyroid disease                                                0.828
    Yes                     11 (7.3%)        12 (8.0%)           
    No                      139 (92.7%)      138 (92.0%)         
  Family history                                                 
    Yes                     12 (8.0%)                            
    No                      138 (92.0%)                          
  Tear size                                                      
    Small                   78 (52.0%)                           
    Medium                  44 (29.3%)                           
    Large                   28 (18.7%)                           
  Pre-operative stiffness                                        
    Yes                     73 (48.7%)                           
    No                      77 (51.3%)                           

Quantitative analysis {#sec3-2}
---------------------

As is shown in [Table 2](#T2){ref-type="table"}, all observed genotype frequencies for the two polymorphisms (rs1799750 and rs3025058) in both controls and patients conformed to HWE, suggesting that these subjects are representative of the total population. The 2G/2G genotype of the rs1799750 polymorphism was significantly associated with a 2.05-fold increased risk of RCT in comparison with 1G/1G (OR = 2.05, 95% CI = 1.06--3.97, *P*=0.033). Moreover, the MMP-1 rs1799750 polymorphism was significantly associated with the risk of RCT in the allelic model (*P*=0.032). The MMP-3 rs3025058 polymorphism was not significantly associated with the risk of RCT. These findings were also confirmed after adjusting for gender and age.

###### Genotype frequencies of MMP1 and MMP3 gene polymorphisms in cases and controls

  Models         Genotype      Case (*n*, %)   Control (*n*, %)   OR (95% CI)             *P*-value   [\*](#T2TFN1){ref-type="table-fn"}OR (95% CI)   [\*](#T2TFN1){ref-type="table-fn"}*P*-value
  -------------- ------------- --------------- ------------------ ----------------------- ----------- ----------------------------------------------- ---------------------------------------------
  rs1799750                                                                                                                                           
  Co-dominant    1G/1G         37 (24.8%)      50 (33.8%)         1.00 (reference)        *-*         1.00 (reference)                                \-
  Heterozygote   1G/2G         74 (49.7%)      73 (49.3%)         1.37 (0.80--2.34)       0.248       1.33 (0.78--2.28)                               0.295
  Homozygote     2G/2G         38 (25.5%)      25 (16.9%)         **2.05 (1.06--3.97)**   **0.033**   **2.01 (1.03-3.89)**                            **0.040**
  Dominant       1G/1G         37 (24.8%)      50 (33.8%)         1.00 (reference)        \-          1.00 (reference)                                \-
                 1G/2G+2G/2G   112 (75.2%)     98 (66.2%)         1.54 (0.93--2.56)       0.091       1.51 (0.91--2.50)                               0.114
  Recessive      1G/1G+1G/2G   111 (74.5%)     123 (83.1%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 2G/2G         38 (25.5%)      25 (16.9%)         1.68 (0.96--2.97)       0.071       1.67 (0.95--2.95)                               0.076
  Allele         1G            148 (49.7%)     173 (58.4%)        1.00 (reference)        *-*         1.00 (reference)                                \-
                 2G            150 (50.3%)     123 (41.6%)        **1.43 (1.03--1.97)**   **0.032**   \-                                              \-
  rs3025058                                                                                                                                           
  Co-dominant    6A/6A         96 (64.0%)      100 (66.7%)        1.00 (reference)        \-          1.00 (reference)                                \-
  Heterozygote   5A/6A         48 (32.0%)      42 (28.0%)         1.19 (0.72--1.96)       0.494       1.15(0.69--1.90)                                0.599
  Homozygote     5A/5A         6 (4.0%)        8 (5.3%)           0.78 (0.26--2.34)       0.659       0.79 (0.26--2.36)                               0.666
  Dominant       6A/6A         96 (64.0%)      100 (66.7%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 5A/6A+5A/5A   54 (36.0%)      50 (33.3%)         1.13 (0.70--1.81)       0.628       1.09 (0.68--1.76)                               0.731
  Recessive      6A/6A+5A/6A   144 (96.0%)     142 (94.7%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 5A/5A         6 (4.0%)        8 (5.3%)           0.74 (0.25--2.19)       0.585       0.75 (0.25--2.23)                               0.609
  Allele         6A            240 (80.0%)     242 (80.7%)        1.00 (reference)        \-          1.00 (reference)                                \-
                 5A            60 (20.0%)      58 (19.3%)         1.04 (0.70--1.56)       0.837       **-**                                           **-**

The genotyping was successful in 149 cases and 148 controls for rs1799750; the genotyping was successful in 150 cases and 150 controls for rs3025058. Bold values are statistically significant (*P*\<0.05).

Adjusted for age and sex.

Stratified analyses were conducted according to gender, smoking and drinking habits, age, hypertension, diabetes and thyroid disease ([Table 3](#T3){ref-type="table"}). When the subjects were stratified according to gender and thyroid disease, no significant difference was found in the frequencies of genotypes and alleles for the rs1799750 polymorphism between the groups. This increased effect of the rs1799750 polymorphism was also evident in subgroups of smokers, drinkers, people aged ≥60 years and subjects with diabetes.

###### Stratified analyses between rs1799750 polymorphisms and the risk of RCT

  Variable          rs1799750 (case/control)   1G/2G vs. 1G/1G   2G/2G vs. 1G/1G   2G/2G vs. 1G/1G +CT            2G/2G +1G/2G vs. 1G/1G                                         
  ----------------- -------------------------- ----------------- ----------------- ------------------------------ ------------------------------- ------------------------------ ------------------------------
  Sex                                                                                                                                                                            
    Male            17/22                      43/34             21/13             1.64 (0.75--3.56); 0.214       2.09 (0.82--5.34); 0.123        1.51 (0.69--3.30); 0.303       1.76 (0.84--3.68); 0.132
    Female          20/28                      31/39             17/12             1.11 (0.53--2.34); 0.778       1.98 (0.78--5.06); 0.151        1.86 (0.82--4.24); 0.140       1.32 (0.66--2.64); 0.437
  Smoking                                                                                                                                                                        
    Yes             17/21                      36/18             17/8              **2.47 (1.05--5.80); 0.038**   2.63 (0.91--7.55); 0.073        1.56 (0.61--3.99); 0.350       **2.52 (1.14--5.57); 0.023**
    No              20/29                      38/55             21/17             1.00 (0.50--2.03); 0.996       1.79 (0.76--4.22); 0.182        1.79 (0.87--3.68); 0.114       1.19 (0.61--2.31); 0.612
  Alcohol                                                                                                                                                                        
    Yes             20/22                      43/26             20/5              1.82 (0.84--3.96); 0.131       **4.40 (1.39--13.92); 0.012**   **3.05 (1.07--8.70); 0.037**   **2.24 (1.06--4.70); 0.034**
    No              17/28                      31/47             18/20             1.09 (0.51--2.31); 0.830       1.48 (0.62--3.56); 0.379        1.41 (0.68--2.93); 0.362       1.21 (0.59--2.44); 0.606
  Age (years)                                                                                                                                                                    
    \<60            31/31                      52/49             27/16             1.06 (0.56--2.00); 0.854       1.69 (0.76--3.73); 0.196        1.63 (0.82--3.24); 0.168       1.22 (0.67--2.21); 0.521
    ≥60             6/19                       22/24             11/9              2.90 (0.98--8.59); 0.054       **3.87 (1.09--13.81); 0.037**   1.88 (0.69--5.11); 0.218       **3.17 (1.12--8.93); 0.029**
  Hypertension                                                                                                                                                                   
    Yes             9/13                       27/22             7/5               1.77 (0.64--4.92); 0.271       2.02 (0.49--8.43); 0.334        1.36 (0.40--4.70); 0.626       1.82 (0.68--4.89); 0.236
    No              28/37                      47/51             31/20             1.22 (0.65--2.29); 0.541       2.05 (0.97--4.32); 0.060        1.82 (0.96--3.45); 0.067       1.45 (0.81--2.61); 0.213
  Diabetes                                                                                                                                                                       
    Yes             10/6                       23/16             6/1               0.86 (0.26-2.85); 0.809        3.60 (0.35-37.60); 0.285        4.00 (0.45-35.54); 0.214       1.02 (0.32-3.32); 0.969
    No              27/44                      51/57             32/24             1.46 (0.79-2.68); 0.226        **2.17 (1.06-4.44); 0.031**     1.73 (0.94-3.17); 0.077        1.67 (0.95-2.95); 0.077
  Thyroid disease                                                                                                                                                                
    Yes             1/2                        6/9               4/1               1.33 (0.10-18.19); 0.829       8.00 (0.31-206.36); 0.210       6.29 (0.58-68.42); 0.131       2.00 (0.16-25.75); 0.595
    No              35/48                      68/64             34/24             1.42 (0.82--2.46); 0.215       1.89 (0.96--3.72); 0.066        1.53 (0.85--2.74); 0.158       1.55 (0.92--2.59); 0.099

Bold values are statistically significant (*P*\<0.05).

Next a possible association was examined between MMP-1 rs1799750 polymorphism and clinicopathological features of patients (tear size, family history and pre-operative stiffness, [Table 4](#T4){ref-type="table"}). The CT or TT genotype was more frequent in patients with pre-operative stiffness compared with patients without pre-operative stiffness, indicating that this polymorphism was associated with pre-operative stiffness in RCT patients.

###### The associations between MMP-1 rs1799750 polymorphism and clinical characteristics of RCT

  Characteristics            Genotype distributions                                                                 
  -------------------------- ------------------------ ------------------------------ ------------------------------ ------------------------------
  Tear size                                                                                                         
    Large/Medium             6/10                     16/18                          6/16                           22/34
    OR (95%CI); *P*-value    1.0 (reference)          1.48(0.44--5.00); 0.525        0.63(0.16--2.49); 0.503        1.08 (0.34--3.39); 0.897
  Tear size                                                                                                         
    Large/Small              6/21                     16/40                          6/16                           22/56
    OR (95% CI; *P*-value    1.0 (reference)          1.40 (0.48--4.11); 0.539       1.31 (0.36--4.84); 0.683       1.38 (0.49--3.86); 0.545
  Family history                                                                                                    
    Yes/No                   3/34                     6/68                           3/35                           9/103
    OR (95% CI); *P*-value   1.0 (reference)          1.00 (0.24--4.25); 1.000       0.97 (0.18--5.15); 0.973       0.99 (0.25--3.87); 0.989
  Pre-operative stiffness                                                                                           
    Yes/No                   12/25                    39/35                          22/16                          61/51
    OR (95% CI); *P*-value   1.0 (reference)          **2.32 (1.02--5.30); 0.043**   **2.87 (1.12--7.35); 0.027**   **2.49 (1.14--5.45); 0.020**

Bold values are statistically significant (*P*\<0.05).

Discussion {#sec4}
==========

The results of the present study showed that the MMP-1 rs1799750 polymorphism conferred susceptibility to RCT, while no significant association was observed with the rs3025058 polymorphism. Subgroup analysis indicated that the MMP-1 rs1799750 polymorphism was associated with an increased risk of RCT among smokers, drinkers, age ≥60 years and subjects without diabetes. Additionally, this polymorphism was associated with pre-operative stiffness in RCT patients.

The MMP-1 rs1799750 polymorphism has been investigated in relation to various diseases, such as ovarian cancer \[[@B14]\], lung cancer \[[@B15]\], glaucoma \[[@B16]\] and osteoarthritis \[[@B17]\]. However, few studies investigated a potential association with the susceptibility to RCT. The frequency of MMP-1 and MMP-9 were significantly more pronounced in the patients with RCT \[[@B17]\]. Up-regulation of MMP-1 and MMP-9 was highly correlated with the failure in the healing of RCT \[[@B18]\]. Therefore, the aim of this research was to focus on the role of MMP-1 rs17799750 polymorphism in the risk of RCT. In a study of 64 patients with full-thickness RCT and 64 asymptomatic control subjects in a Brazilian population, Assuncao et al. \[[@B13]\] found that MMP-1 rs7799750 polymorphism was associated with the risk of RCT in homozygous, heterozygous and allelic models; the results of our study are consistent with this report despite performed in a different population. Furthermore, the significant association appeared strong among smokers, drinkers, people aged ≥60 years and subjects without diabetes. Therefore, our hypothesis was that the rs1799750 polymorphism is involved in the development of RCT by regulating the activity and production of MMP-1.

Similarly, the association between the MMP3 rs3025058 polymorphism and disease risk has been widely investigated for conditions such as ischemic stroke \[[@B19]\], coronary disease \[[@B20]\], chronic obstructive pulmonary disease \[[@B21]\] and abdominal aortic aneurysm \[[@B22]\]. Only one study evaluated the role of MMP3 rs3025058 polymorphism in the risk of RCT \[[@B13]\] and it is again the one of Assuncao et al. \[[@B13]\] in a Brazilian (Caucasian) population. Their case--control study involving 64 cases and 64 controls showed that the 5A/5A genotype or 5A allele was associated with an increased risk of RCT. However, in our study, no significant association was observed in the eastern Chinese (Asian) population (150 cases and 150 controls), demonstrating the importance of validating the role of this polymorphism in other races. Three reasons might account for the conflicting results between Asians and Caucasians. First, a difference exists in allele frequency of the MMP-3 rs3025058 polymorphism among these ethnic groups. Second, different genotyping methods and random errors might contribute to these discrepancies. Third, the sample size of the Caucasian population (64 cases and 64 controls) was not sufficient to reach a convincing conclusion in comparison with Asian populations.

Several potential limitations might influence our results. First, the lack of available original data prevented the adjustment for other covariates, such as diet and lifestyle. Second, we could not rule out the possibility of random discoveries due to the limited sample size. Third, since RCT is a multifactorial disease, single nucleotide polymorphisms have a limited impact. Fourth, the included controls might not represent the overall population of East China because this is a hospital-based case--control study. Thus, higher powered studies in a large population, as well as functional evaluation of the studied polymorphism are needed to confirm the findings of the present study.

Despite these limitations, our work demonstrated that MMP-1 rs1799750 polymorphism is a genetic contributor to the risk of RCT and can be used as a biomarker for early screening and treatment of RCT.
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